Haizhou Lou

668 citations
21 papers · 379 indexed · h-index 10
Topics
Lung Cancer Treatments and Mutations (5 papers)Colorectal Cancer Treatments and Studies (4 papers)Hepatocellular Carcinoma Treatment and Prognosis (3 papers)
Partner nations
ChinaNepalUnited States

In The Last Decade

Haizhou Lou

19 papers receiving 375 citations

Peers

Haizhou Lou
Comparison fields: 5 of 71
  • Molecular Biology 121
  • Hepatology 119
  • Oncology 107
  • Epidemiology 88
  • Pulmonary and Respiratory Medicine 67
Replace Cailing Gan with:
Cailing Gan China
Li Liang China
Yuko Kita Japan
Soo Teik Lee South Korea
Wenmin Yao China
Ya-Ju Du China
Jana Y. Wo Hong Kong
I. Sordelli Italy
Jianzhuang Ren China
Haizhou Lou relative to Cailing Gan China Cailing Gan's profile →
Citations per field
00.5×3.9×
Cailing Gan · 1×
Citations per year

Countries citing papers authored by Haizhou Lou

Since Specialization
Citations

This map shows the geographic impact of Haizhou Lou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haizhou Lou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haizhou Lou more than expected).

Fields of papers citing papers by Haizhou Lou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haizhou Lou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haizhou Lou. The network helps show where Haizhou Lou may publish in the future.

Co-authorship network of co-authors of Haizhou Lou

This figure shows the co-authorship network connecting the top 25 collaborators of Haizhou Lou. A scholar is included among the top collaborators of Haizhou Lou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haizhou Lou. Haizhou Lou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 0
4 23
5 4
6 9
7 3
8 20
9 15
10 1
11 3
12 5
13 1
14 5
15 4
16 25
17 9
18 43
19 73
20
[Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation].
11

About Haizhou Lou

Haizhou Lou is a scholar working on Hepatology, Oncology and Toxicology, having authored 21 papers that have together received 379 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). The work is most often cited by research in Hepatology (119 citations), Cancer Research (59 citations) and Oncology (107 citations). Haizhou Lou has collaborated with scholars based in China, Nepal and United States. Frequent co-authors include Hongming Pan, Pan Qin, Da Li, Yong Fang, Yinghua Xu, Kaifeng Wang, Xiao Liang, Wei Chen, Lü Tian and Jianxin Chen. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026